Clinical Third antibody treatment for early COVID infection approved by...

Third antibody treatment for early COVID infection approved by the FDA


The United States FDA ( Food and Drug Administration) has approved the monoclonal antibody therapy treatment of Vir Biotechnology and GSK ( GlaxoSmithKline) on Wednesday, for acute COVID-19 infections, according to the agency.

It is the 3rd antibody therapy that has been approved to be used in patients who are in the initial phases of the disease and are at higher risk of acquiring serious infections. FDA stated that the medication is “ expected” to protect from different strains of Coronavirus.

In March, both firms stated that an interim analysis had found the medication to be highly effective in minimizing hospitalization and deaths related to Covid-19.

According to some reports, the United States has acquired the medication directly from the production companies and made it available to the patients through clinical and hospital settings.

Vir and GSK, unlike their antecedents, do not have any agreement with the federal government, according to the Wall Street Journal. The businesses will be required to sell the medication on a commercial basis.

The director of the Center for Drug Evaluation and Research of the FDA, Patrizia Cavazzoni stated, “With the authorization of this monoclonal antibody treatment, we are providing another option to help keep high-risk patients with COVID-19 out of the hospital.”
“It is important to expand the arsenal of monoclonal antibody therapies that are expected to retain activity against the circulating variants of COVID-19 in the United States.”

+ posts

Latest news

Revvity introduces advanced preclinical imaging tech for scientists to make breakthroughs

Revvity, Inc. is ushering in a new era of innovation in the realm of preclinical research by...

European Commission Approves Updated Pfizer-BioNTech Vaccine for Omicron XBB.1.5 Variant

The European Commission has recently achieved a significant milestone in the ongoing battle against COVID-19 in preparation...

NICE gives Chiesi’s Elfabrio go ahead

Chiesi has recently garnered a favorable recommendation from the National Institute for Health and Care Excellence (NICE)...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you